Clinical Trials Logo

Filter by:
NCT ID: NCT06366581 Completed - Incisional Hernia Clinical Trials

Transcriptomic Analysis of Incisional Hernia Based on High-throughput Sequencing Technology

Start date: March 1, 2023
Phase:
Study type: Observational

This study included patients who underwent surgical treatment for incisional hernia and non-hernia conditions. Surgical specimens were collected for transcriptome sequencing to obtain the gene expression list. Then genes analyzed by Gene Ontology, protein interactions, and signaling pathway enrichment using the expression matrix.

NCT ID: NCT06366529 Recruiting - Clinical trials for Renal Insufficiency, Chronic

Explore New Magnetic Resonance Technology in Assessment of Renal Dysfunction

Start date: September 1, 2023
Phase:
Study type: Observational

Currently, renal biopsy is the gold standard for evaluating renal pathology and renal fibrosis, but it is invasive and carries the risk of serious complications; and the sampled tissue is only a small part of the kidney, which is prone to sampling bias. The lack of reliable, comprehensive test results has hindered the research of new anti-fibrotic drugs and delayed the clinical application of effective new drugs. Therefore, the development of a non-invasive dynamic detection method for renal insufficiency and renal fibrosis in vivo is an urgent clinical problem to be solved. With the continuous development and update of technology, imaging provides a new way to non-invasively evaluate renal fibrosis. Due to the high resolution of soft tissue and the ability to perform multi-parameter analysis, magnetic resonance has developed the diagnosis of renal insufficiency and renal fibrosis from macroscopic simple biomorphological changes to microscopically complex pathophysiological changes. Many imaging techniques measure renal dysfunction and renal fibrosis by assessing the impact of fibrosis on the functional status, physical properties, and molecular properties of the kidney. In recent years, in the context of precision medicine, artificial intelligence technologies such as radiomics and machine learning are rapidly becoming very promising auxiliary tools in the imaging assessment of renal fibrosis. It can extract and learn features in images with high throughput, make greater use of information in medical images that cannot be recognized by the human eye, and achieve disease diagnosis, prognosis assessment, and efficacy prediction by building models. However, most of the current research is in the preliminary stage, and there are still few studies on the assessment of renal insufficiency and renal fibrosis. I believe that with the continuous improvement of algorithms and the optimization of models, the progress of radiomics and machine learning will be great. To a certain extent, it promotes the development of personalized medicine and precision medicine for patients with renal insufficiency and renal fibrosis.

NCT ID: NCT06366516 Not yet recruiting - Clinical trials for Precancerous Cervical Lesion

Role of Methylation Test Triage in HPV Positive Women

MTTRIHPW
Start date: April 2024
Phase: N/A
Study type: Interventional

The pathological results were used as the gold standard in this study and the investigators analyze the diagnostic value of six gene methylation status (ASTN1 DLX1, ITGA4, RXFP3, SOX17, ZNF671) in triaging high-risk human papillomavirus infection. The sensitivity and specificity of methylation test and cytology in the diagnosis of high-grade cervical lesions are compared in order to providing new methods and basis in improving the accuracy of cervical cancer screening.

NCT ID: NCT06366048 Active, not recruiting - Liver Failure Clinical Trials

A Study on Relationship Between Resected Normal Liver Parenchymal Volume(RNLV)and Post-Hepatectomy Liver Failure (PHLF)

RNLV
Start date: December 1, 2022
Phase:
Study type: Observational

The post-hepatotectomy liver failure (PHLF) is still the most worrisome complication of hepatic resection. Surgeons have always been making efforts to preoperatively predict PHLF using kinds of techniques, scoring systems, and variables. The investigators of this study tried to create an individual predictive model based on the variable, resected normal parenchymal volume (RNLV), then assessing the performance and value of the model in clinical practice.

NCT ID: NCT06365814 Completed - Gastric Cancer Clinical Trials

ERAS for Gastric Cancer Patients After NACT

Start date: October 1, 2023
Phase:
Study type: Observational

Background: Gastric cancer patients receiving neoadjuvant chemotherapy (NACT) are more vulnerable to perioperative stress. Enhanced recovery after surgery (ERAS) is widely used in surgical patients aiming at reducing stress responses. However, whether this approach is safe and feasible for gastric cancer patients received minimally invasive radical gastrectomy after NACT remained determined. So, the objective of this study is to investigate the effects of ERAS for this special group of gastric cancer patients. Materials and Methods: The data of gastric cancer patients who underwent minimally invasive radical gastrectomy after NACT were collected in this retrospective cohort study. Patients were divided into an ERAS group and a conventional group based on whether they received perioperative ERAS management. Propensity score matching was conducted to eliminate bias. Pre- and postoperative inflammatory and nutritional marker levels, postoperative complications, recovery indices and 3-year OS and RFS were observed.

NCT ID: NCT06365697 Not yet recruiting - Clinical trials for Carotid Artery Stenosis

Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis

Start date: May 2024
Phase: N/A
Study type: Interventional

The purpose of this trial is to evaluate effectiveness and safety of the Ton-bridge carotid stent for the treatment of carotid artery stenosis.

NCT ID: NCT06365580 Recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Dose Escalation Study of Kylo-0603 in Healthy Subjects

Start date: May 23, 2023
Phase: Phase 1
Study type: Interventional

This clinical trial is the first-in-human study of Kylo-0603. The purpose of this randomized, double-blind, placebo-controlled phase 1 study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and effect of food of Kylo-0603 in healthy Chinese adult subjects.

NCT ID: NCT06365541 Recruiting - Clinical trials for The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

Start date: March 1, 2024
Phase: Phase 4
Study type: Interventional

Dialysis patients have a higher incidence of cardiovascular events and require more effective measures to delay the progression of heart failure. Many studies have shown that dapagliflozin has cardioprotective effect, but most studies focus on non-dialysis patients with eGFR more than 20ml/min/1.73m2. However, the data on patients with eGFR less than 20ml/min/1.73m2 or dialysis patients, especially peritoneal dialysis patients, is less. Exploring the efficacy and safety of Dapagliflozin in improving heart failure in dialysis patients is of great clinical significance.

NCT ID: NCT06365502 Recruiting - Clinical trials for Acute Coronary Syndrome (ACS)

Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial)

Start date: April 16, 2024
Phase: N/A
Study type: Interventional

The objective of this multicenter, prospective, open-label, controlled, randomized trial is to demonstrate the superiority of drug-coated balloon (DCB) treatment on non-flow limited vulnerable plaque as compared to guideline-directed medical therapy (GDMT) in improving clinical cardiovascular outcomes in patients with acute coronary syndrome.

NCT ID: NCT06365424 Recruiting - Clinical trials for Primary Biliary Cholangitis

Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)

Start date: April 8, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

An Open Label Long-Term Study to Evaluate the Safety and Effectiveness of Fenofibrate in Subjects with Primary Biliary Cholangitis (PBC)